http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f6876ba7877b44a64e26d77a3c42f6c0
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Bast |
| name | Robert C Bast Robert C. Bast |
| given-name | Robert C Robert C. |
| organization-name | Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah... Department of Experimental Therapeutics University of Texas M.D. Anderson Cancer Center Houston TX USA University of Texas MD Anderson Cancer Center, Houston, TX Authors' Affiliations: 1Departments of Bioengineering and Chemistry, Rice University; Departments of 2Gynecologic Oncology and 3Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston; 4Departments of Chemistry and Biochemistry, The University of Texas at Austin, Austin; Departments of 5Pathology and 6Dental Diagnostic Science, University of Texas Health Science Center at San Antonio, San Antonio, Texas. From the Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and AstraZeneca Pharmaceuticals LP, Wilmington, DE. The University of Texas M. D. Anderson Cancer Center, Houston, TX James Homer Wright Pathology Laboratories of the Massachusetts General Hospital From the , Boston, Massachusetts Authors' Affiliations: 1Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama; 2Department of Gynecologic Oncology, U.T.M.D. Anderson Cancer Center, Houston, Texas; 3Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; 4Department of Experimental Therapeutics, U.T.M.D. Anderson Cancer Center, Houston, Texas; 5The University of Puerto Rico Comprehensive Cancer Center, Rio Piedras, PR; and 6Center for RNA Interference and Non-Coding RNA; 7Department of Cancer Biology, U.T.M.D. Anderson Cancer Center, Houston, Texas Department of Experimental Therapeutics MD Anderson Cancer Center, University of Texas Houston Texas Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX From the Department of Gynecological Oncology, Institute of Women's Health, University College London, London; Biostatistics Centre, MA General Hospital, and Harvard Medical School, Boston, MA; US Department of Gynecological Oncology, Barts and The London NHS Trust, London Department of Clinical Biochemistry, University College London Hospital, London Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas 77054, United States Departments of Medicine, North Chicago, Illinois; Departments of Immunology and the Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, North Chicago, Illinois Departments of 1Molecular and Cellular Oncology, 2Experimental Therapeutics, 3Breast Medical Oncology, 4Stem Cell Transplantation and Cellular Therapy, and 5Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center; 6The University of Texas Graduate School of Biomedical Sciences, Houston, Texas; 7Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University and Hospital; 8Asia University, Taichung, Taiwan; and 9Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China 6Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. University of Texas MD Anderson Cancer Center, Houston, Texas. rbast@mdanderson.org. 1Experimental Therapeutics, Departments of Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston 1Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas. 6University of Texas, MD Anderson Cancer Center, Houston, Texas. Department of Experimental Therapeutics; University of Texas MD Anderson Cancer Center; USA Duke University Medical Center, Durham, NC, U.S.A. 1Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, Texas. MD Anderson Cancer Center, Houston, Texas, 77030; 2Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and Department of Experimental Therapeutics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, U.S.A. 2University of Texas M.D. Anderson Cancer Center, Houston, Texas; and 6Translational Research and Departments of Pathology, Harvard Medical School and Massachusetts General Hospital From the , Boston, Massachusetts 02114 1Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and Department of Experimental Therapeutics, M.D. Anderson Cancer Center, University of Texas, Houston, TX 77030, USA Departments of Medicine, Microbiology and Immunology, and Pathology and the Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, and Department of Immunology, Cetus Corporation, Emeryville, California M. D. Anderson Cancer Center, Houston, TX, USA. 2M. D. Anderson Cancer Center, Houston, Texas; Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA From the Massachusetts General Hospital and Harvard Medical School, Boston, MA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Duke University Medical Center, Durham, NC; Johns Hopkins Medical Institutions, Baltimore, MD; Groningen University Hospital, Groningen, the Netherlands; and St Bartholomew’s Hospital, London, United Kingdom The University of Texas M.D. Anderson Cancer Center, Department of Experimental Therapeutics, Houston, TX, USA. Division of Medicine and Department of Molecular Genetics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030; and Department of Laboratory Medicine, University of California, San Francisco, CA 94143 2Experimental Therapeutics, and 4Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas Veterans Administration Hospital, Washington, D.C. From the University of Pittsburgh Cancer Institute; Departments of Epidemiology, Pathology, Medicine, and Obstetrics/Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh; Fox Chase Cancer Center, Philadelphia, PA; Biostatistics Center, Massachusetts General Hospital; Harvard Medical School, Boston; Department of Physics, Massachusetts Institute of Technology, Cambridge, MA; Department of Surgery, Duke University Medical Center, Durham, NC; Departments of Gynecologic Oncology and... 1University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 77030 Experimental Therapeutics, and Department of Molecular Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; and Department of Molecular and Medical Genetics, Ontario Cancer Institute and University of Toronto, Toronto, ON, Canada, M5G 2M9 Department of the Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina.; Department of Medicine, Duke University Medical Center, Durham, North Carolina.; Department of Microbiology/Immmunology, Duke University Medical Center, Durham, North Carolina. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States Experimental Therapeutics, the University of Texas M.D. Anderson Cancer Center, Houston TX 77030 USA. Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA 4Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Authors' Affiliations: 1Department of Experimental Therapeutics; 2Bioinformatics and Computational Biology, MD Anderson Cancer Center, University of Texas, Houston, Texas; 3Nuffield Department of Obstetrics and Gynaecology; and 4Department of Oncology, University of Oxford, Oxford, United Kingdom Biology Branch, National Cancer Institute, National Institutes of Health From the , Bethesda, Maryland 20014 M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA. avy University of Texas, MD Anderson Cancer Center , Department of Experimental Therapeutics , Houston , TX , USA. 2Department of Translational Research, University of Texas M. D. Anderson Cancer Center, Houston, Texas; The University of Texas MD Anderson Cancer Center, Houston, TX Department of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA Department of Experimental Therapeutics, ‡Department of Thoracic and Cardiovascular Surgery, and §Department of Biochemistry and Molecular Biology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, United States Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology and Anatomic Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. 1Ovarian Cancer Research Laboratory, Department of Experimental Therapeutics, and Departments of Departments of Medicine, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030 Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology, Anatomic Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA 3Experimental Therapeutics, and 1Department of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas. Office of Translational Research The University of Texas MD Anderson Cancer Center Houston Texas Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, United States Departments of Experimental Therapeutics, U.T.M.D. Anderson Cancer Center, Houston, TX 77030, USA the Department of Experimental Therapeutics (R.C.B.), University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030 Department of Experimental Therapeutics University of Texas, M.D. Anderson Cancer Center Houston TX 4Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Authors' Affiliations: 1Graduate Institute of Cancer Biology, College of Medicine, China Medical University; 2Center for Molecular Medicine, China Medical University Hospital; 3Department of Biotechnology, Asia University, Taichung, Taiwan; Departments of 4Molecular and Cellular Oncology, 5Experimental Therapeutics, and 6Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 7Institute of Toxicology, College of Medicine, National Taiwan University; and 8The Genomics Research Center, Academic Sinica, Taipei, Taiwan 2Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. From the James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Boston, Massachusetts 02114 Authors' Affiliations: Departments of Experimental Therapeutics and Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas Authors' Affiliations: 1Brigham and Women's Hospital, Boston, Massachusetts; 2MD Anderson Cancer Center, Houston, Texas; 3Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland; 4Biochemistry, Mount Sinai Hospital, Toronto, Ontario, Canada; 5Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas; 6Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland; 7University of Pittsburgh, Pittsburgh, Pennsylvania; 8Fred Hutchinson Cancer Research Center, Seattle, Washington; 9Yale University, New Haven, Connecticut; 10Cancer Biomarker Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland; 11University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; 12Massaschusetts General Hospital, Boston, Massachusetts; 13Cancer Research Center, University of Honolulu, Hawaii; and 14Johns Hopkins University, Baltimore, Maryl Department of Pathology, Massachusetts General Hospital, Departments of Medicine, Pathology and Obstetrics and Gynecology, Brigham and Women’s Hospital, Division of Tumor Immunology, Sidney Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Robert C. Bast, Ana M. Gonzalez-Angulo, and William F. Symmans, University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Texas Oncology, Dallas, TX; Massimo Cristofanilli, Thomas Jefferson University–Kimmel Cancer Center, Philadelphia, PA; Matthew P. Goetz and Minetta C. Liu, Mayo Clinic, Rochester, MN;... |
Incoming Links
Total number of triples: 413.